Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sangamo and Sigma-Aldrich team up with Roche

This article was originally published in Scrip

Executive Summary

Sigma-Aldrichand Sangamo BioScienceshave reached a research and licensing agreement with Rocheto provide non-exclusive, worldwide rights to the use of their proprietary zinc finger nuclease (ZFN) technology to develop cell lines and transgenic animals with targeted genetic modifications. Roche also has an option to an exclusive worldwide licence for the commercial use of ZFN-generated transgenic animals in the production of therapeutic and diagnostic products. Zinc finger DNA-binding proteins are the major form of transcription factor found in cells and they bind to DNA to regulate gene expression. ZFNs are zinc finger DNA-binding proteins that are engineered to contain a nuclease component, and can target particular genes precisely to produce knock-out animals as disease models. The research phase of the agreement will be conducted in collaboration with both Sangamo and Sigma-Aldrich, which has an exclusive licence to the ZFN technology for high-value research reagents. Under the agreement, Roche will pay research fees, and if it elects to exercise its option for an exclusive commercial licence will owe Sangamo an option licence fee, additional payments on achievement of clinical development events and royalties on sales of therapeutic and diagnostic products developed by Roche using the ZFN-modified animals.

You may also be interested in...

On-Site Inspections Of US Device Makers Plummet 93% As FDA Scrambles For Virtual Solutions

A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.

EU Health Ministers To Deliberate Over Commission’s Pharma Strategy

A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.

Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle

Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts